ERBB2 and breast carcinoma: HER2, EGFR1, EGFRvIII and the PI3K/PTEN/Akt/mTORC1 pathway are clearly important not only in the development of breast cancer, but also in the classification and prognosis of breast cancer patients which display mutations or changes in the expression of components of these pathways.